Generex Biotechnology Announces Appointment of New Independent Director

13-Feb-2004

Generex Biotechnology Corporation, a leader in the area of buccal drug delivery, announced the appointment of Mindy J. Allport-Settle as an independent member of the Company's board of directors effective February 6, 2004. Ms. Allport-Settle has been the President & Chief Executive Officer of Integrated Development, LLC since 1998 and a Vice-President of Impact Management services, Inc. since 2003. The appointment of Ms. Allport-Settle as an independent director helps the Company meet the requirements under the Sarbanes-Oxley Act of 2002.

Integrated Development and Impact Management Services are independent consulting firms to the pharmaceuticals industry, providing informed guidance in operational, project and contract management, new business development and regulatory compliance. Ms. Allport-Settle has worked with companies such as GlaxoSmithKline, Pfizer, AstraZeneca, Johnson Controls and DSM Pharmaceuticals. She is currently working on her Masters Degree in Business Administration in Global Management at the University of Phoenix.

"We are very pleased that an individual with Mindy's extensive knowledge of and experience in the pharmaceuticals industry, particularly in the area of regulatory compliance, has agreed to join our board of directors," said Anna Gluskin, the President & Chief Executive Officer of Generex. "She is sure to make a valuable addition to the Company's board as we aggressively pursue the clinical and regulatory programs for Oralin(TM), our proprietary oral insulin spray formulation, and our other products."

https://www.bionity.com/en/news/35257/generex-biotechnology-announces-appointment-of-new-independent-director.html